The IMID Forum

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Saturday, June 15).

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of EULAR 2024 (Friday, June 14).

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of EULAR 2024 (Thursday, June 13).

Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Wednesday, June 12).

Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.

Join Professor Janet Pope and Dr Sofia Ramiro on The IMID Forum as they discuss the long-term safety of JAK inhibitors in RA. They delve into papers comparing tofacitinib versus TNFi in cardiovascular risk and the efficacy of upadacitinib over five years. The podcast also explores the importance of proper treatment to reduce risks and the balancing act of benefits versus risks in JAK inhibitor prescriptions for inflammatory diseases.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dorthe Berthelsen, a PhD student and physiotherapist at the Parker Institute in Copenhagen and at the University of Southern Denmark, as they discuss her recent paper ‘“I couldn't carry on taking a drug like that”: A qualitative study of patient perspectives on side effects from rheumatology drugs.’

Webinar Highlights Podcast: Join Professor Iain McInnes and Associate Professor Laura Coates on the Immune-Mediated Inflammatory Disease Forum in their discussion on the recent webinar “Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar”. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the pathophysiology of IL-23 inhibitors compared with TNF and IL-17 inhibitor therapies, and the relationship between IL-23 inhibitor MOA variation and real-world patient data.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jake Weddell, an academic rheumatology trainee at Leeds Teaching Hospitals NHS Trust, as they discuss his recent paper ‘Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.’

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Frank Verhoeven, an Assistant Professor in Rheumatology at the CHU Besancon in France, as they discuss his recent paper ‘Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis.’